Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis

다국어 초록 (Multilingual Abstract)

Background: Aromatase inhibitors (AIs) play an important role in the endocrine therapy of postmenopausal breast cancer patients, with a recent tendency to extend the duration of their use. However, AIs may increase the risk of osteoporotic bone fractures. This meta-analysis evaluated the risk of osteoporotic fractures of the hip, spine, and other locations in breast cancer patients using AIs.
Methods: We performed a systematic search to identify randomized controlled clinical trials that investigated osteoporotic fractures in breast cancer patients on AI therapy. The main outcomes were the incidence and risk of osteoporotic fractures in general and of hip, vertebral, and non-vertebral fractures in AI users and controls.
Results: The systematic review found a total of 30 randomized controlled trials including 117,974 participants. The meta-analysis showed a higher incidence of osteoporotic fracture in AI users: The crude risk ratio for all osteoporotic fractures was 1.35 (95% confidence interval [CI], 1.29–1.42; P < 0.001), for hip fractures 1.18 (95% CI, 1.02–1.35; P < 0.001), for vertebral fractures 1.84 (95% CI, 1.36–2.49; P < 0.001), and for non-vertebral fractures 1.18 (95% CI, 1.02–1.35; P < 0.001), respectively, compared to the controls.
Conclusion: Our meta-analysis suggested an increased risk of osteoporotic fractures for AI therapy in patients with breast cancer that was most expressed for vertebral fractures. Breast cancer patients on AIs need to be monitored for osteoporosis and osteoporotic fractures, and active prevention measures should be implemented.

참고문헌 (Reference)

1 Buzdar AU, "‘Arimidex’(anastrozole)versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview" 86 (86): 399-403, 2003

2 Schardt C, "Utilization of the PICO framework to improve searching for clinical questions" 7 (7): 16-, 2007

3 Howlader N, "US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status" 106 (106): dju055-, 2014

4 Amir E, "Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients : a systematic review and meta-analysis" 103 (103): 1299-1309, 2011

5 Forbes JF, "The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial" 33 (33): S2-S7, 2006

6 Park C, "The incidence and residual lifetime risk of osteoporosisrelated fractures in Korea" 29 (29): 744-751, 2011

7 Baum M, "The current status of aromatase inhibitors in the management of breast cancer" 83 (83): 973-994, 2003

8 Higgins JP, "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials" 343 : d5928-, 2011

9 Becker T, "Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer" 60 (60): 1761-1767, 2012

10 Boccardo F, "Switching to anastrozole versus continued tamoxifen treatment of early breast cancer : preliminary results of the Italian Tamoxifen Anastrozole Trial" 23 (23): 5138-5147, 2005

11 Boccardo F, "Switching to anastrozole versus continued tamoxifen treatment of early breast cancer : long term results of the Italian Tamoxifen Anastrozole trial" 49 (49): 1546-1554, 2013

12 Jakesz R, "Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen : combined results of ABCSG trial 8 and ARNO 95 trial" 366 (366): 455-462, 2005

13 Mauri D, "Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer : meta-analysis" 98 (98): 1285-1291, 2006

14 Coleman RE, "Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study(IES) : a randomised controlled study" 8 (8): 119-127, 2007

15 Venken K, "Sex hormones, their receptors and bone health" 19 (19): 1517-1525, 2008

16 Goss PE, "Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer : updated findings from NCIC CTG MA. 17" 97 (97): 1262-1271, 2005

17 R Core Team, "R : a Language and Environment for Statistical Computing" R Foundation for Statistical Computing 2020

18 Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement" 6 (6): e1000097-, 2009

19 Baatjes KJ, "Postmenopausal breast cancer, aromatase inhibitors, and bone health : what the surgeon should know" 40 (40): 2149-2156, 2016

20 Cooper C, "Population-based study of survival after osteoporotic fractures" 137 (137): 1001-1005, 1993

21 Aihara T, "Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer : N-SAS BC03 study" 121 (121): 379-387, 2010

22 유제현, "Osteoporotic Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research" 대한골대사학회 22 (22): 175-181, 2015

23 Begg CB, "Operating characteristics of a rank correlation test for publication bias" 50 (50): 1088-1101, 1994

24 Lee SJ, "Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast cancer" 97 (97): 551-559, 2015

25 Dowsett M, "Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen" 28 (28): 509-518, 2010

26 Hadji P, "Management of aromatase inhibitorassociated bone loss(AIBL)in postmenopausal women with hormone sensitive breast cancer : joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG" 7 : 1-12, 2017

27 BIG 1-98 Collaborative Group, "Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer" 361 (361): 766-776, 2009

28 Crivellari D, "Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer : the BIG 1-98 trial" 26 (26): 1972-1979, 2008

29 Goss PE, "Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen" 26 (26): 1948-1955, 2008

30 Yap YS, "Insights into breast cancer in the East vs the West:a review" 2019

31 Body JJ, "Increased fracture rate in women with breast cancer : a review of the hidden risk" 11 (11): 384-, 2011

32 윤현구, "Incidence and Mortality Following Hip Fracture in Korea" 대한의학회 26 (26): 1087-1092, 2011

33 Kaufmann M, "Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen : the ARNO 95 Study" 25 (25): 2664-2670, 2007

34 Rizzoli R, "Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer : an ESCEO position paper" 23 (23): 2567-2576, 2012

35 Melton LJ 3rd, "Fracture risk in women with breast cancer : a population-based study" 27 (27): 1196-1205, 2012

36 Neuner JM, "Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients" 22 (22): 2847-2855, 2011

37 Coates AS, "Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer : update of study BIG 1-98" 25 (25): 486-492, 2007

38 Goss PE, "Extending aromatase-inhibitor adjuvant therapy to 10 years" 375 (375): 209-219, 2016

39 Goss PE, "Exemestane for breast-cancer prevention in postmenopausal women" 364 (364): 2381-2391, 2011

40 Khosla S, "Estrogen and the skeleton" 23 (23): 576-581, 2012

41 Cummings SR, "Epidemiology and outcomes of osteoporotic fractures" 359 (359): 1761-1767, 2002

42 Gnant M, "Endocrine therapy plus zoledronic acid in premenopausal breast cancer" 360 (360): 679-691, 2009

43 Lønning PE, "Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer" 23 (23): 5126-5137, 2005

44 Bliss JM, "Disease-related outcomes with longterm follow-up : an updated analysis of the intergroup exemestane study" 30 (30): 709-717, 2012

45 Geisler J, "Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane : a randomised, placebo-controlled study" 42 (42): 2968-2975, 2006

46 Taxel P, "Cancer treatment-induced bone loss in women with breast cancer and men with prostate cancer" 2 (2): 574-588, 2018

47 Edwards BJ, "Cancer therapy associated bone loss : implications for hip fractures in mid-life women with breast cancer" 17 (17): 560-568, 2011

48 Rabaglio M, "Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial" 20 (20): 1489-1498, 2009

49 Egger M, "Bias in meta-analysis detected by a simple, graphical test" 315 (315): 629-634, 1997

50 Mamounas EP, "Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen : intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial" 26 (26): 1965-1971, 2008

51 Early Breast Cancer Trialists' Collaborative Group(EBCTCG), "Aromatase inhibitors versus tamoxifen in early breast cancer : patient-level meta-analysis of the randomised trials" 386 (386): 1341-1352, 2015

52 Smith IE, "Aromatase inhibitors in breast cancer" 348 (348): 2431-2442, 2003

53 Colleoni M, "Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study" 29 (29): 1117-1124, 2011

54 Winer EP, "American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer : status report 2004" 23 (23): 619-629, 2005

55 Hillner BE, "American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer" 21 (21): 4042-4057, 2003

56 Pagani O, "Adjuvant exemestane with ovarian suppression in premenopausal breast cancer" 371 (371): 107-118, 2014

57 Gnant M, "Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer : 62-month followup from the ABCSG-12 randomised trial" 12 (12): 631-641, 2011

58 Howell A, "Adjuvant aromatase inhibitors for breast cancer" 366 (366): 431-433, 2005

59 Goss PE, "A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer" 349 (349): 1793-1802, 2003

60 Coombes RC, "A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer" 350 (350): 1081-1092, 2004

61 Breast International Group(BIG)1-98 Collaborative Group, "A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer" 353 (353): 2747-2757, 2005